Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 1/20 | 0.68 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.68 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.68 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.62 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18481365 | 0.79 | ITGA4 (0.51) | GRK5TYRO3DYRK1BITGA4ITGB7 | |
| SCHEMBL18481366 | 0.79 | ITGA4 (0.55) | GRK5TYRO3DYRK1BITGA4ITGB7 | |
| SCHEMBL11713352 | 0.78 | KDM4E (0.54) | GRK5TYRO3DYRK1BITGA4ITGB7 | |
| SCHEMBL11057466 | 0.75 | ITGA4 (0.47) | GRK5TYRO3DYRK1BITGA4ITGB7 | |
| SCHEMBL11555543 | 0.75 | ITGA4 (0.47) | GRK5TYRO3DYRK1BITGA4ITGB7 | |
| SCHEMBL16280099 | 0.75 | MGLL (0.62) | GRK5TYRO3DYRK1BMEN1KMT2A | |
| SCHEMBL5906008 | 0.74 | ITGA4 (0.58) | GRK5TYRO3DYRK1BITGA4ITGB7 | |
| SCHEMBL13164871 | 0.73 | MEN1 (1.00) | ITGA4ITGB7MEN1KMT2AMAPT | |
| SCHEMBL16322903 | 0.73 | ALOX5 (0.47) | GRK5TYRO3DYRK1BITGA4ITGB7 | |
| SCHEMBL2851080 | 0.70 | MGLL (0.56) | GRK5TYRO3DYRK1BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| EP-2632916-B1 | NOVEL ANTI-CANCER AGENTS | THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) | 2017-01-11 | — | — | EP | disclosed |
| US-20160145243-A1 | Novel Anti-Cancer Agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2016-05-26 | — | — | US | disclosed |
| US-9221799-B2 | Anti-cancer agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-12-29 | — | — | US | disclosed |
| US-20150045365-A1 | Novel Anti-Cancer Agents | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-12 | — | — | US | disclosed |
| US-8835629-B2 | Anti-cancer agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2014-09-16 | — | — | US | disclosed |
| US-20130261119-A1 | Novel Anti-Cancer Agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-10-03 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| EP-2632916-A1 | NOVEL ANTI-CANCER AGENTS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2013-09-04 | — | — | EP | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| US-4283547-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1981-08-11 | — | — | US | disclosed |
| US-3937626-A | 2,4,5-TRIOXO-IMIDAZOLIDINE-3-CARBOXYLIC ACID AMIDES | CIBA-GEIGY CORPORATION (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045365-A1 | Novel Anti-Cancer Agents | TP53, SLC10A1, HDAC6 | GRK5 653/4885TYRO3 3236/4885DYRK1B 4124/4885 |
| US-20130261119-A1 | Novel Anti-Cancer Agents | TP53, SLC10A1, ARFGAP1 | GRK5 578/4885TYRO3 2965/4885DYRK1B 4172/4885 |
| US-20160145243-A1 | Novel Anti-Cancer Agents | TP53, SLC10A1, HDAC6 | GRK5 653/4885TYRO3 3236/4885DYRK1B 4124/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | GRK5 132/4885TYRO3 603/4885DYRK1B 1244/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | GRK5 451/4885TYRO3 11/4885DYRK1B 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.